Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the immune system. Our approach flips the script: we isolate...
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordability to patients and health care systems JERSEY CITY, N.J., Oct. 31, 2024 /PRNewswire/ --...
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission. The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with metastatic NSCLC. Long-term survival data...
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China in...
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients
ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the immune system. Our approach...
MGI’s DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024
SHENZHEN, China, Oct. 31, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Special Mention in the TIME Best Inventions 2024 list. TIME Best...
Abionic’s CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration
DONGGUAN, China, Oct. 31, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership with Abionic SA and LASCCO SA, Fapon has gained exclusive rights to utilize the...
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF bispecific antibody ivonescimab in combination with Akeso's next-generation CD47 monoclonal antibody ligufalimab (AK117) against pembrolizumab for...
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position
RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 31, 2024 /PRNewswire/ -- Recently Frost & Sullivan researched the AI-based stroke imaging solutions industry and, based on its findings, recognizes RapidAI with the 2024 Company of the Year Award. The...
Registries using Internet Watch Foundation, Public Interest Registry protections triple in crackdown on commercial child sexual abuse gangs
New partnership provides protection from child sexual abuse material for 37,842,025 new domains in six months 'Now is the time' to act, with IWF protection available at no cost, thanks to sponsorship by Public Interest Registry. CAMBRIDGE, United Kingdom, Oct. 30, 2024 /PRNewswire/ -- A "landmark" drive to target criminal gangs...
